ART

CTN 016: Acemennan

A Pilot Controlled Double Blind Study of Acemennan in Patients Receiving AZT for the Treatment of Advanced HIV Disease

CTNPT 007: Hypophosphatemia and renal monitoring in HIV

Renal monitoring in people living with HIV

CTN 003: Multi-centre AZT trial

Multi-centre AZT Trial (MCAT): Trial results

CTN 002: ddI, continued AZT

Double Blind Comparison of ddI and Continued Zidovudine (AZT) in Therapy of Patients with HIV-Related Immune Suppression: Trial results

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

Fanconi syndrome due to ARVs in HIV-infected persons

Vicriviroc in HIV treatment-experienced people

Vicriviroc in combination treatment with an optimized ART regimen in HIV-infected treatment-experienced subjects

Ritonavir-boosted elvitegravir versus raltegravir

A Multicenter, randomized, double-blind, double-dummy, phase 3 study of the safety and efficacy of Ritonavir-boosted Elvitegravir (EVG/r) versus Raltegravir (RAL)

Extended release nevirapine QD in treatment-naïve (VERxVE study)

A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID neVirapinE immediate release in combination with Truvada™ in antiretroviral therapy naïve HIV-1 infected patients. (VERxVE study)(Trial number 1100.1486)